Ethan Oren Perlstein

Ethan Oren Perlstein

Auto-generated profile, based on publicly available information

Ethan Oren Perlstein

Perlara PBC

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2007 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
SSSovan Sarkar
Sovan Sarkar
EPEthan O Perlstein
Ethan O Perlstein
SISara Imarisio
Sara Imarisio
SPSandra Pineau
Sandra Pineau
ACAxelle Cordenier
Axelle Cordenier
David C RubinszteinDavid C Rubinsztein
David C Rubinsztein

20 August 2004 in Genome Biology
Verified
Journal Article
Open access
BBBradley E Bernstein
Bradley E Bernstein
CLChih Long Liu
Chih Long Liu
EHEmily L Humphrey
Emily L Humphrey
EPEthan O Perlstein
Ethan O Perlstein
SSStuart L Schreiber
Stuart L Schreiber
Background: Although eukaryotic genomes are generally thought to be entirely chromatin-associated, the activated PHO5 promoter in yeast is largely devoid of nucleosomes. We systematically evaluated nucleosome occupancy in yeast promoters by immunoprecipitating nucleosomal DNA and quantifying enrichment by microarrays. Results: Nucleosome depletion is observed in promoters that regulate active genes and/or contain multiple evolutionarily conserved motifs that recruit transcription factors. The Rap1 consensus was the only binding motif identified in a completely unbiased search of nucleosome-depleted promoters. Nucleosome depletion in the vicinity of Rap1 consensus sites in ribosomal protein gene promoters was also observed by real-time PCR and micrococcal nuclease digestion. Nucleosome occupancy in these regions was increased by the small molecule rapamycin or, in the case of the RPS11B promoter, by removing the Rap1 consensus sites. Conclusions: The presence of transcription factor-binding motifs is an important determinant of nucleosome depletion. Most motifs are associated with marked depletion only when they appear in combination, consistent with a model in which transcription factors act collaboratively to exclude nucleosomes and gain access to target sites in the DNA. In contrast, Rap1-binding sites cause marked depletion under steady-state conditions. We speculate that nucleosome depletion enables Rap1 to define chromatin domains and alter them in response to environmental cues.

19 November 2004 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
MLMichael M.-C. Lo
Michael M.-C. Lo
CNChristopher S. Neumann
Christopher S. Neumann
SNSatoshi Nagayama
Satoshi Nagayama
EPEthan O. Perlstein
Ethan O. Perlstein
SSStuart L. Schreiber
Stuart L. Schreiber

4 March 2007 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
EPEthan O Perlstein
Ethan O Perlstein
DRDouglas M Ruderfer
Douglas M Ruderfer
DRDavid C Roberts
David C Roberts
SSStuart L Schreiber
Stuart L Schreiber
LKLeonid Kruglyak
Leonid Kruglyak

15 January 2006 in Nature Chemical Biology
Verified
Journal Article
Closed access
RBRebecca A Butcher
Rebecca A Butcher
BBBhupinder S Bhullar
Bhupinder S Bhullar
EPEthan O Perlstein
Ethan O Perlstein
GMGerald Marsischky
Gerald Marsischky
JLJoshua LaBaer
Joshua LaBaer
SSStuart L Schreiber
Stuart L Schreiber

1 January 2019 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
SISangeetha Iyer
Sangeetha Iyer
FSFeba S. Sam
Feba S. Sam
NDNina DiPrimio
Nina DiPrimio
GPGraeme James Preston
Graeme James Preston
JVJan Verheijen
Jan Verheijen
EPEthan O. Perlstein
Ethan O. Perlstein
Phosphomannomutase 2 deficiency, or PMM2-CDG, is the most common congenital disorder of glycosylation affecting over 1,000 patients globally. There are no approved drugs that treat the symptoms or root cause of PMM2-CDG. In order to identify clinically actionable compounds that boost human PMM2 enzyme function, we performed a multi-species drug repurposing screen using a first-ever worm model of PMM2-CDG followed by PMM2 enzyme functional studies in PMM2-CDG patient fibroblasts. Drug repurposing candidates from this study, and drug repurposing candidates from a previously published study using yeast models of PMM2-CDG, were tested for their effect on human PMM2 enzyme activity in PMM2-CDG fibroblasts. Of the 20 repurposing candidates discovered in the worm-based phenotypic screen, 12 are plant-based polyphenols. Insights from structure-activity relationships revealed epalrestat, the only antidiabetic aldose reductase inhibitor approved for use in humans, as a first-in-class PMM2 enzyme activator. Epalrestat increased PMM2 enzymatic activity in four PMM2-CDG patient fibroblast lines with genotypes R141H/F119L, R141H/E139K, R141H/N216I and R141H/F183S. PMM2 enzyme activity gains range from 30% to 400% over baseline depending on genotype. Pharmacological inhibition of aldose reductase by epalrestat may shunt glucose from the polyol pathway to glucose-1,6-bisphosphate, which is an endogenous stabilizer and coactivator of PMM2 homodimerization. Epalrestat is a safe, oral and brain penetrant drug that was approved 27 years ago in Japan to treat diabetic neuropathy in geriatric populations. We demonstrate that epalrestat is the first small molecule activator of PMM2 enzyme activity with the potential to treat peripheral neuropathy and correct the underlying enzyme deficiency in a majority of pediatric and adult PMM2-CDG patients.